Drug Discovery World

NOVEMBER 7, 2022

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases. . Dr Pitceathly continued: “In this study, every new genetic diagnosis had a direct impact on patient care.

Genome 52

Genome Genomics Genetics Genetic Disease 52

Drug Discovery World

APRIL 18, 2023

DDW’s Megan Thomas rounds up highlights from Tuesday 17 April at AACR 2023, from AI and mathematical oncology to winners of the AACR James S Ewing-Thelma B Dunn Award for Outstanding Achievement in Pathology in Cancer Research. Read more here. Read more here.

Genetics 52

Genetics DNA Research Bioinformatics 52

Drug Discovery World

JULY 29, 2022

Scientists from seven research institutions including the University of Oxford and the University of Edinburgh have used pioneering bioinformatic modelling to investigate the molecular interactions of the p53 protein known to give protection against cancers.

Gene 52

Gene DNA Protein Genetics 52

Scienmag

MAY 27, 2021

Cellular proteins get their marching orders from genetic instructions encoded in DNA, whose sequences are first copied and made […].

Gene Expression 41

Gene Expression RNA DNA Protein 41

Scienmag

APRIL 8, 2021

Credit: IRB Barcelona In cancer, personalised medicine takes advantage of the unique genetic changes in an individual tumour to find its vulnerabilities and fight it. Many tumours have a higher number of mutations due to a antiviral defence mechanism, the APOBEC system, which can accidentally damage DNA and cause mutations.

Scientist 53

Scientist DNA Genetics Medicine 53

Scienmag

MARCH 12, 2021

UMD-led research identifies age-related changes to DNA and reveals longevity-related differences between bat species Credit: G. Tschapka A new study led by University of Maryland and UCLA researchers found that DNA from tissue samples can be used to accurately predict the age of bats in the wild. Wilkinson, G.

DNA 98

DNA Research Bioinformatics Genetics 98

XTalks

DECEMBER 13, 2023

In 2023, biotechnology and pharmaceutical companies leverage cutting-edge technology and significant investments in research and development (R&D) to continue pushing the boundaries of innovation in the healthcare sector, transcending the challenges posed by the pandemic.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Scienmag

APRIL 20, 2021

This can result in patchy data that fall short of what researchers need to anticipate and address outbreaks. Real-world disease and parasite monitoring is often hampered by the inability of traditional approaches to easily sample broad geographical areas and large numbers of individuals.

RNA 72

RNA DNA Research Bioinformatics 72

Drug Discovery World

JULY 26, 2023

An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. Research increasingly demonstrates that within each discrete microbial environment (e.g., Research increasingly demonstrates that within each discrete microbial environment (e.g.,

Medicine 52

Medicine Genome Genomics Bioinformatics 52

XTalks

SEPTEMBER 28, 2020

Based on the genetic biomarker(s) identified, the most effective therapy targeting the specific molecular marker can be selected. The test involves isolating circulating tumor DNA in the blood and sequencing it to look for relevant gene mutations.

Gene 105

Gene DNA Life Science Genotype 105

Drug Discovery World

APRIL 14, 2023

The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. June’s award lecture will be held on Sunday April 16 at 4:30pm ET.

Genetics 52

Genetics Research Medicine Clinical Research 52

pharmaphorum

SEPTEMBER 14, 2020

Last week geneticist Dr Charles Steward shared with us his experiences of searching for a genetic cause for his children’s rare neurological diseases. While it is a very rare form of epilepsy, it is such a cheap and harmless medication that it is often used as a first-line therapy for infants in intensive care who have no genetic diagnosis.

Genome 108

Genome Genomics Medicine Gene 108

Drug Discovery World

APRIL 14, 2023

At the beginning of 2023, proteomics company Nautilus Biotechnology announced a partnership with the Translational Genomics Research Institute (TGen), to study the specific proteins at work in the rare and often fatal childhood cancer, diffuse intrinsic pontine glioma (DIPG).

Protein 52

Protein Genome Genomics DNA 52

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). These tumor-derived entities are used to derive genomic and proteomic data.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. In a boone for Slonim’s research focus, the year 2020 has made this molecule a household name.

Vaccination 52

Vaccination Vaccine Regulation Drugs 52